Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields

Research Will Be Performed Using Novocure’s inovitro™ System – a Laboratory Research System That Allows Researchers to Apply TTFields to Cancer Cells in Culture ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today that Novocure’s inovitro™ laboratory research system will be used to study Tumor Treating Fields (TTFields) therapy at The University of Texas MD Anderson …

Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a computational study analyzing the effect of transducer layout on Tumor Treating Fields, or TTFields, distribution has been published in the International Journal of Radiation Oncology • Biology • Physics, also known as the Red Journal. The study results suggest that customizing transducer array layouts based …

Humana Issues Positive Coverage Decision For Optune

More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that Humana now covers Optune for members who have recurrent glioblastoma (GBM). Humana is the ninth commercial payer in the United States to issue a positive coverage policy for …